Tech Company Financing Transactions
Seraxis Funding Round
Seraxis, based in Germantown, scored $40 million from Eli Lilly and Company, Frazier Healthcare Partners and JDRF T1D Fund.
Transaction Overview
Company Name
Announced On
2/10/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to complete the preclinical testing of SR-01, its lead cell therapy treatment for insulin-dependent diabetes and initiate first-in-human clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20271 Goldenrod Ln. 2085
Germantown, MD 20876
USA
Germantown, MD 20876
USA
Phone
Undisclosed
Website
Email Address
Overview
Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes. Our team of scientists have developed a novel cell and immune-evasion technologies that, together, reverse diabetes in animal models.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Rust
VP - Bus. Development
Carole Welsch
Browse more venture capital transactions:
Prev: 2/10/2021: Swift Navigation venture capital transaction
Next: 2/10/2021: Symend venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs